Perlmutter Cancer Center

The purpose of the study is to assess the safety and tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab. XmAb®22841 is a humanized bispecific monoclonal antibody (bsAb) that binds the immune checkpoint molecules cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte-activation gene 3 (LAG3) in order to block signaling in the tumor microenvironment(TME) that prevents activated T cells from attacking and clearing tumor cells from the body. The study drug XmAb®22841 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.